Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)

Acta Oncologica

Volumn 52, Issue 8, 2013, Pages 1786-1788

  Kelderman, Sander ^a   Van Der Kooij, Monique K ^b   Van Den Eertwegh, Alfons J M ^c   Soetekouw, Patricia M M B ^d   Jansen, Rob L H ^d   Van Den Brom, Rob R H ^e   Hospers, Geke A P ^e   Haanen, John B A G ^a   Kapiteijn, Ellen ^b   Blank, Christian U ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PREDNISOLONE; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; COHORT ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; METASTASIS; NETHERLANDS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UVEA MELANOMA; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COLITIS; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; HEPATITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM STAGING; NETHERLANDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UVEAL NEOPLASMS;

EID: 84885464333     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.786839     Document Type: Letter

References (8)

1. Sato T, Han F, Yamamoto A. The biology and management of uveal melanoma. Curr Oncol Rep 2008; 10: 431-8.
2. Hodi FS, O'Day SJ, McDermott DF, Weber R W, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363: 711-23.
3. Khan SA, Callahan MK, Postow M, Chapman P, Schwartz G, Dickson M, et al. Ipilimumab in the treatement of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience. Abstract #8549, ASCO Annual Meeting. 2012.
4. Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy. Cancer Immunol Immunother 2012; 61: 41-8.
5. Maio M, Sileni VC, Pilla L, Nicoletti SVL, Di Guardo L, Queirolo P, et al. Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: Experience from Italian clinics participating in the European Expanded Access Programme. Abstract #1133P, ESMO Annual Meeting. 2012.
6. Lawrence D, McDermott D, Hamid O, Weber J, Wolchok J, Richard J, et al. Treatment of patients (pts) with stage III or IV melanoma on an ipilimumab (Ipi) expanded access program (EAP): Results for 3mg/kg cohort. Poster, SMR meeting. 2012.
7. Maker A V, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005; 12: 1005-16.
8. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011; 364: 2517-26.